---
schema_version: "secwatch.filing_event.v1"
accession: "0001116463-25-000008"
form_type: "8-K/A"
ticker: "OSUR"
cik: "0001116463"
company_name: "ORASURE TECHNOLOGIES INC"
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T02:58:46.159150+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition

## Summary
- Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
- Accumulated deficit reached $149.7M as of Sep 30, 2024; total liabilities $55.3M exceed assets $31.1M.
- Cash and cash equivalents $3.8M at Sep 30, 2024; convertible notes of $27.9M outstanding.
- Revenue from grants only $1.1M in 9 months 2024, $0.9M in FY2023; no product revenue.
- Going concern uncertainty noted, but expected to be resolved by OraSure acquisition in Dec 2024.

## SEC filing metadata
- accession: 0001116463-25-000008
- form_type: 8-K/A
- ticker: OSUR
- cik: 0001116463
- company_name: ORASURE TECHNOLOGIES INC
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1116463/000111646325000008/0001116463-25-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1116463/000111646325000008/osur-20241219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001116463-25-000008
- JSON: https://secwatch.observer/filing/0001116463-25-000008.json
- Plain text: https://secwatch.observer/filing/0001116463-25-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.